Haverford Trust Co Acquires 31,314 Shares of Eli Lilly and Company $LLY

Key Points

• Haverford Trust Co increased its stake in Eli Lilly and Company by 82.2%, acquiring an additional 31,314 shares, bringing its total holdings to 69,389 shares valued at approximately $57.3 million.
• Several institutional investors have recently restructured their stakes in Eli Lilly, with 82.53% of the company's stock now owned by institutional investors.
• Eli Lilly's recent earnings report indicated $6.31 EPS and $15.56 billion in revenue, surpassing analyst estimates, while a quarterly dividend of $1.50 per share was also announced.

Haverford Trust Co raised its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 82.2% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 69,389 shares of the company's stock after buying an additional 31,314 shares during the period. Haverford Trust Co's holdings in Eli Lilly and Company were worth $57,309,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Knightsbridge Asset Management LLC raised its stake in Eli Lilly and Company by 1.9% in the fourth quarter. Knightsbridge Asset Management LLC now owns 813 shares of the company's stock valued at $628,000 after buying an additional 15 shares during the period. Corient IA LLC bought a new position in shares of Eli Lilly and Company during the first quarter worth approximately $570,000. LS Investment Advisors LLC increased its stake in shares of Eli Lilly and Company by 1.7% during the first quarter. LS Investment Advisors LLC now owns 2,340 shares of the company's stock worth $1,933,000 after purchasing an additional 40 shares during the period. Prism Advisors Inc. bought a new position in shares of Eli Lilly and Company during the first quarter worth approximately $207,000. Finally, Hemington Wealth Management increased its stake in shares of Eli Lilly and Company by 14.4% during the first quarter. Hemington Wealth Management now owns 985 shares of the company's stock worth $813,000 after purchasing an additional 124 shares during the period. Institutional investors own 82.53% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on LLY. Morgan Stanley reiterated an "overweight" rating and set a $1,135.00 target price (up previously from $1,133.00) on shares of Eli Lilly and Company in a research note on Thursday, July 10th. HSBC lowered Eli Lilly and Company from a "buy" rating to a "reduce" rating and lowered their target price for the stock from $1,150.00 to $700.00 in a research note on Monday, April 28th. Daiwa America lowered Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research note on Sunday, August 17th. Deutsche Bank Aktiengesellschaft lowered their target price on Eli Lilly and Company from $1,010.00 to $900.00 and set a "buy" rating on the stock in a research note on Monday, August 11th. Finally, UBS Group lowered their target price on Eli Lilly and Company from $1,050.00 to $895.00 and set a "buy" rating on the stock in a research note on Friday, August 8th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $950.17.

Insider Transactions at Eli Lilly and Company

In other Eli Lilly and Company news, Director J Erik Fyrwald bought 1,565 shares of Eli Lilly and Company stock in a transaction on Tuesday, August 12th. The shares were purchased at an average price of $642.33 per share, with a total value of $1,005,246.45. Following the acquisition, the director owned 74,578 shares in the company, valued at $47,903,686.74. This trade represents a 2.14% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Daniel Skovronsky bought 1,000 shares of Eli Lilly and Company stock in a transaction on Tuesday, August 12th. The stock was acquired at an average cost of $634.40 per share, for a total transaction of $634,400.00. Following the acquisition, the executive vice president owned 137,660 shares in the company, valued at approximately $87,331,504. This represents a 0.73% increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders have acquired 4,514 shares of company stock worth $2,894,841. 0.13% of the stock is owned by insiders.

Eli Lilly and Company Trading Up 0.1%

Shares of NYSE:LLY opened at $710.7290 on Friday. The company has a market capitalization of $672.68 billion, a P/E ratio of 46.45, a P/E/G ratio of 0.99 and a beta of 0.44. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $972.48. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. The business's 50 day simple moving average is $754.70 and its 200 day simple moving average is $790.90.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.59 by $0.72. The business had revenue of $15.56 billion for the quarter, compared to the consensus estimate of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The firm's quarterly revenue was up 37.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted $3.92 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, research analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th will be issued a $1.50 dividend. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.8%. The ex-dividend date of this dividend is Friday, August 15th. Eli Lilly and Company's dividend payout ratio (DPR) is currently 39.22%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.